Market Overview

Trovagene to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Share:

SAN DIEGO, Sept. 3, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today announced it will be presenting at the H.C. Wainwright 21st Annual Global Investment Conference at 10:50 a.m. Eastern time on Tuesday, September 10, 2019. The conference is being held September 8-10, 2019 at the Lotte New York Palace Hotel.

Trovagene is a clinical-stage oncology therapeutics company, using a precision medicine predictive biomarker approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers. Onvansertib, its lead drug candidate, is a first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor.  The Company currently has two ongoing open-label clinical trials: a Phase 1b/2 trial in acute myeloid leukemia (AML) and a Phase 2 trial in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Thomas Adams, Chief Executive Officer and Chairman, and Dr. Mark Erlander, Chief Scientific Officer of Trovagene, will provide an overview of the Company's business during the live presentation and will be available for one-on-one meetings with investors.

Institutional investors who would like to attend the company's presentation should click here to register for the conference.  Once registered, you can log into the conference website to request a one-on-one meeting. 

The presentation will be webcast live.  To access the webcast, please click here. The webcast replay will remain available for 90 days following the live presentation.

About Trovagene, Inc.

Trovagene is a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics.  For more information, please visit https://www.trovageneoncology.com.

Trovagene Contact:
Vicki Kelemen
VP, Clinical Development and Investor Relations
858-952-7652
vkelemen@trovagene.com 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-hc-wainwright-21st-annual-global-investment-conference-300909790.html

SOURCE Trovagene, Inc.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com